Hematology
Refine search
Biotechnology
US biotech Biogen and its Chinese partner TJ Biopharma announced that felzartamab for injection - branded Jingfei in China - has been approved by China's National Medical Products Administration (NMPA) for use with lenalidomide and dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy. 17 August 2026
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 14 August 2026
Biotechnology
London-based biotech firm Silence Therapeutics said on Monday that lead candidate divesiran met the primary endpoint of the Phase II SANRECO trial in polycythemia vera (PV), a rare blood cancer in which the bone marrow overproduces red blood cells. Shares rose sharply on the news, touching a 52-week high. 11 August 2026
Biotechnology
French rare diseases company Innate Pharma (and Swedish Orphan Biovitrum (Sobi) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase III study in cutaneous T-cell lymphoma (CTCL). 10 August 2026
Pharmaceutical
M&A news continued last week, with Curium announcing it is acquiring fellow US radiopharmaceutical company Lantheum for around $8 billion. A heavily financial results week included second quarter figures from US pharma giants Merck & Co and Pfizer. Also of note, the US Food and Drug Administration finally granted approval for Replimune’s Tudriqev for melanoma. 9 August 2026
Biotechnology
The National Institute for Health and Care Excellence (NICE) has recommended two acalabrutinib-based combinations for National Health Service (NHS) use in England and Wales, Anglo-Swedish pharma major AstraZeneca announced. 6 August 2026
Pharmaceutical
US pharma major Eli Lilly reported second-quarter 2026 revenue of $23 billion, up 48% year-on-year from $15.6 billion in the second quarter of 2025 and well ahead of Wall Street forecasts of around $20.7 billion. 6 August 2026
Biotechnology
US biotech Amgen reported a 10% increase in second-quarter 2026 revenue, as growth from Repatha (evolocumab), Evenity (romosozumab) and several newer medicines outweighed declining sales of products facing pricing or biosimilar pressure. 5 August 2026
Biotechnology
South Korean immune-oncology company Vaxcellbio revealed it has signed a strategic memorandum of understanding (MOU) with Canadian biotechnology company Myellama to jointly develop a novel multiple myeloma therapy based on the National Research Council Canada's (NRC) next-generation NK cell engager technology. 4 August 2026
Pharmaceutical
US pharma major Bristol Myers Squibb has raised its full-year outlook after second-quarter 2026 revenue and earnings came in well above analyst expectations, helped by strong demand for Eliquis (apixaban) and continued growth from newer medicines. 31 July 2026
Pharmaceutical
US privately-held plasma fractionator Octapharma has formally announced plans to establish its first-ever USA -based manufacturing and production site at the Palmetto Research Park in Rock Hill, South Carolina. 30 July 2026
Pharmaceutical
French pharma major Sanofi has raised its 2026 guidance after second-quarter sales and business earnings beat expectations, helped by continued growth for Dupixent (dupilumab) and recently launched medicines. 30 July 2026
Biotechnology
USA-based cell therapy company Legend Biotech has named Alan Bash as interim chief executive after Ying Huang stepped down from the role and resigned from the board. 28 July 2026
Pharmaceutical
Anglo-Swedish pharma major AstraZeneca reported higher second-quarter revenues, helped by continued growth in oncology and rare diseases, while core earnings beat market expectations despite pressure from Farxiga’s loss of US exclusivity and China volume-based procurement. 27 July 2026
Biotechnology
Among significant news last week, Halozyme Therapeutics struck a license agreement for its INCA033989 with fellow USA-based Incyte. South Korea’s Samsung Biologics announced plans to acquire Swiss firm PolyPeptide for around $1.8 billion. On the research front, Celldex released mixed results for its barzolvolimab in prurigo nodularis, and its decision to discontinue development in this indication. French major Sanofi announced it will discontinue development of amlitelimab in atopic dermatitis. 26 July 2026
Biotechnology
US pharma major Johnson & Johnson has reported positive top-line Phase III data showing that a dual bispecific antibody regimen sharply improved survival outcomes in patients with relapsed or refractory multiple myeloma. 24 July 2026
Pharmaceutical
Roche today posted first-half 2026 financial results that beat analysts’ expectations, pushing the Swiss pharma major’s shares up 3.2% to 343.00 francs. 23 July 2026
Pharmaceutical
Cambridge, USA-based Agios Pharmaceuticals’ shares fell as much as 14% today after the company announced it would discontinue development of tebapivat in sickle cell disease following Phase II trial results. 21 July 2026
Biotechnology
Germany’s Allogenetics today announced the appointment of Dr Jeroen Rovers as chief medical officer (CMO). 21 July 2026
Pharmaceutical
Halozyme Therapeutics today announced that it has entered into a global collaboration and license agreement with Incyte. 20 July 2026
Biotechnology
CSL Ltd shares are being hammered after the Australian biotech released another painful update to the market, with the stock closing down 16% at A$100.75, having fallen as much as 20%. 11 May 2026
Biotechnology
UK clinical-stage biotech CellCentric has announced the completion of an oversubscribed $220 million Series D financing. 7 May 2026
Biotechnology
US biotech Vertex Pharmaceuticals today announced that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel). 6 May 2026
Pharmaceutical
US biopharma company Veradermics last week reported encouraging top-line Phase II/III results for its hair loss treatment VDPHL01. On the M&A front, Eli Lilly announced it is to acquire Ajax Therapeutics for up to $2.3 billion along with its hematology candidate AJ1-110915. Also, Chiesi announced a takeover of USA-based KalVista Pharma and its Ekterly to expand its rare diseases portfolio. US biotech AnaptysBio won a favorable court ruling in its dispute with GSK/Tesaro over cancer drug Jemperli. 3 May 2026
Biotechnology
Hemab Therapeutics Holdings, a Phase III-ready biotech developing blood coagulation disorder treatments, has announced terms for its initial public offering (IPO). 1 May 2026
Pharmaceutical
US pharma major Eli Lilly delivered a standout first quarter of 2026, with financial results comfortably exceeding market expectations. 30 April 2026
Pharmaceutical
US pharma major Bristol Myers Squibb has reported better-than-expected financial results for the first quarter of 2026, with revenues rising 3% year-on-year to $11.49 billion, ahead of analyst forecasts of around $10.9 billion. 30 April 2026
Biotechnology
US pharma giant Pfizer has announced positive topline results from the Phase III MagnetisMM-5 study of Elrexfio (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. 30 April 2026
Biotechnology
The New England Journal of Medicine (NEJM) has published 26-week results from the Phase III FRONTIER2 trial evaluating the efficacy and safety of once-monthly and once-weekly Mim8 (denecimig) in adults and adolescents 12 years of age and older with hemophilia A (congenital Factor VIII (FVIII) deficiency), with or without FVIII inhibitors. Investigational denecimig is a bispecific antibody Factor VIIIa (FVIIIa) mimetic, designed for routine prophylaxis to help the body form blood clots. 30 April 2026
Biotechnology
Chinese biopharma Hutchmed today announced that the New Drug Application (NDA) for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration (NMPA). 29 April 2026
Biotechnology
Gilead Sciences and its Kite Oncology subsidiary have announced that the European Medicines Agency (EMA) has approved a Type II variation to the Summary of Product Characteristics (SmPC) for its approved chimeric antigen receptor (CAR) T-cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). 28 April 2026
Biotechnology
Swedish Orphan Biovitrum, also known as Sobi, reported first-quarter revenue in line with expectations, while adjusted operating profit (EBITA) exceeded analyst forecasts. 28 April 2026
Biotechnology
US pharma major Eli Lilly is continuing its M&A spending spree, today announcing a definitive agreement to acquire Ajax Therapeutics, a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs). 27 April 2026
Pharmaceutical
Among significant news last week, Denmark’s Novo Nordisk presented positive results for its sickle cell disease candidate etavopivat. Eli Lilly revealed an up to $7 billion deal to acquire Kelonia Therapeutics and its gene therapy KLN-1010. The US Centers for Medicaid and Medicare Services (CMS) has extended the GLP-1 Bridge program for obesity medicines as insurers hold back. US biopharma Grace Therapeutics suffered a setback as the US Food and Drug Administration (FDA) issued a complete response letter (CRL) on the company’s new drug application (NDA) for GTx-104, which is being developed for aneurysmal subarachnoid hemorrhage (aSAH). 26 April 2026
Pharmaceutical
US biopharma Grace Therapeutics has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its New Drug Application (NDA) for GTx-104, sending the company’s shares down by 45% in Thursday's trading. 24 April 2026
Pharmaceutical
In the first three months of 2026, Swiss pharma giant Roche sales were up6% at constant exchange rates (CER), down 5% when reported in Swiss francs, to.7 billion francs ($18.7 billion) due to strong demand for pharmaceutical products and diagnostic solutions. 23 April 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved Sanofi’s supplemental biologic license application for Tzield (teplizumab-mzwv), expanding the indication from eight years and older to as young as one year of age to delay the onset of stage 3 type 1 diabetes (T1D) in patients diagnosed with stage 2 T1D. 22 April 2026
Biotechnology
British pharma GSK has won approval in China for Blenrep (belantamab mafodotin) with bortezomib and dexamethasone in relapsed or refractory multiple myeloma after at least one prior therapy. 21 April 2026
Biotechnology
Danish pharma major Novo Nordisk today announced the top-line results from HIBISCUS, a pivotal Phase III trial of once-daily oral etavopivat in adults and adolescents with sickle cell disease (SCD). 20 April 2026
Pharmaceutical
Spanish plasma-derived medicines company Grifols announced that it has successfully completed the refinancing of its 2027 debt maturities through a new credit agreement structured as a Term Loan B (TLB), alongside a revolving credit facility. 17 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze